Seppro Tech Buy Adds to Sigma-Aldrich’s Protein-Depletion, Antibody Product Lines | GenomeWeb
Sigma-Aldrich this week said it has expanded its protein-depletion and antibody product line by acquiring GenWay Biotech’s Seppro technology.
 
The transaction covers two separate but related products: the Seppro affinity-depletion technology and a library of 700 avian-derived antibodies.
 
Included in the deal are the current Seppro inventory, the production technology, and all future rights to produce and distribute the product lines, Sigma-Aldrich said in a statement.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.